Tagworks will present on the preclinical development of the first-in-class click-cleavable ADC TGW101, targeting non-internalizing pan-carcinoma marker TAG72; as well as TGW211, a first-in-class HER2-directed radioimmunoconjugate.  This presentation is part of the Engineering ADC Conjugates session on November 12, 2025, starting at 11.45 in Lisbon, Portugal.

https://www.pegsummiteurope.com